Evidence map›Paper›PMID 42718878›Full record

Trial reportBlood neoplasia2026

Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients.

Vincenzo J Pizzuti, Angela Dunn, Kathryn Colborn, Mckenzie Schubat, Thomas Althaus, Shakhara Harris, Jamie L Studts, Sarah J Schmiege, Paul F Cook, Tyler W Buckner and 5 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vincenzo J PizzutiDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO.
Angela DunnAdult and Child Center for Outcomes Research and Delivery Science, University of Colorado School of Medicine, Aurora, CO.
Kathryn ColbornAdult and Child Center for Outcomes Research and Delivery Science, University of Colorado School of Medicine, Aurora, CO.
Mckenzie SchubatSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
Thomas AlthausSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
Shakhara HarrisSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
Jamie L StudtsDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
Sarah J SchmiegeCenter for Innovative Design & Analysis, Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO.
Paul F CookDivision of Behavioral, Family & Population Health, University of Colorado College of Nursing, Aurora, CO.
Tyler W BucknerDivision of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
Benjamin W BrewerDivision of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
Justin KlineSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
Michael R BishopSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
Peter A RiedellSection of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
Ajay MajorDivision of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Health-related quality of life (HRQoL) measured by patient-reported outcomes (PROs) is understudied in patients who receive chimeric antigen receptor T-cell (CAR-T) therapies. We hypothesized that CAR-T therapies generate long-term HRQoL benefits, and that PRO trajectories in the immediate postinfusion period may serve as prognostic indicators for treatment response. We measured longitudinal HRQoL among patients with hematologic malignancies receiving CAR-T therapy using the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health-10 and PROMIS-29 Profile instruments at 13 time points over a 2-year period after CAR-T therapy. PROs were analyzed by linear mixed-effect modeling. We enrolled 83 patients, mostly with aggressive lymphomas (49%) and myeloma (43%). Long-term improvements in physical and social role functioning as well as sleep were observed in the entire study cohort at 2 years after CAR-T therapy, regardless of whether patients were aged ≤65 or >65 years. Women reported improvements in fatigue (

Identifiers

PMID42718878
PMCPMC13553519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.